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Background/aim: Leptin is a hormone that is known to be related to weight gain and obesity. The soluble leptin receptor has been found
in plasma as an important determinant of leptin sensitivity. In this study, our goal was to investigate the association between leptin levels
and leptin receptor polymorphisms in a Turkish population.
Materials and methods: The sample pool of this study consisted of 202 subjects. G2548A variant in the promoter region of the leptin
gene and Q223R polymorphism of the leptin receptor gene were evaluated by using PCR-RFLP. Leptin levels were determined by ELISA.
Results: Leptin levels were significantly higher in subjects with the A allele than in subjects without the A allele. Leptin receptor levels
were lower in subjects with the AA genotype than in those with the AG genotype. There was a higher prevalence of the leptin-2548 AA
genotype among subjects with a BMI ≥ 25 kg/m2 than in those with a BMI < 25 kg/m2.
Conclusion: The leptin-2548A allele might be a predisposing factor for obesity.
Key words: Leptin, leptin receptor, obesity

1. Introduction
Obesity is a major public health problem that contributes
to the pathogenesis of several severe chronic diseases
including cardiovascular disease, diabetes, and certain
kinds of cancer. Leptin is an essential hormone related to
weight gain and obesity, controlling energy balance and
metabolism in the human body. It is a peptide hormone,
secreted from white adipose tissue as a signal to the
brain, and has a primary influence on body weight by
coordinating the metabolic, endocrine, and behavioral
responses to starvation (1). Insensitivity of the leptin
receptor is known as leptin resistance. Free leptin levels
were found to be correlated with leptin resistance, BMI,
and fat mass (2). Leptin receptor is a member of the class-1
cytokine receptor family and it is an important determinant
of leptin sensitivity originally found in hypothalamic
neurons. However, alongside the membrane-bound forms
of this receptor, there is also a soluble form in plasma
(1). The function of this soluble form is not known yet,
* Correspondence: tisbir@superonline.com

but it is thought to contribute to the delay in clearance
of leptin (3). An inverse relationship was found between
leptin and soluble leptin receptor levels (4). The balance
between bound and free leptin depends on the plasma
concentration of this soluble leptin receptor (1,5). The
ratio between total and soluble leptin concentration was
used as the free leptin index, indicating leptin resistance
(5).
Genetic studies about leptin and leptin receptor
mutations revealed that those patients who had
homozygous mutations of these gene regions had severe
gonadal and thyroid abnormalities, delayed puberty, and
dramatic increase in weight (6). In this aspect, the effects
of polymorphisms on leptin and leptin levels were also
evaluated and the Gln223Arg (Q223R) polymorphism
of the leptin receptor was found to lead to an amino acid
change in the extracellular domain that is common for all
isoforms of the receptor affecting the charge of the region
and leptin binding capacity (7).
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The leptin gene region G-2548A variant exists in the
promoter region, affecting the functional capacity of leptin.
The 2548A allele was found to be positively correlated with
elevated serum leptin concentrations (8,9). The objective of
our study was to evaluate the association between serum leptin
and soluble leptin receptor levels and their polymorphisms in
conjunction with changes in body mass indices.
2. Materials and methods
2.1. Study groups
The study group consisted of 202 subjects chosen from
the population of patients who applied to İstanbul Bilim

University Hospital’s Internal Medicine Clinics for regular
health examinations. Subjects without any major chronic
disease were included in the study. Written informed
consent was obtained from each subject. Clinical variables
of the study groups are given in Table 1.
2.2. Specimen supply
Immediately upon arrival, whole blood samples were
centrifuged and aliquoted; they were afterwards stored at
–30 °C.
2.3. DNA extraction
The genomic DNA samples of the subjects were isolated
from venous whole blood samples (from leukocytes) by a

Table 1. Clinical variables of subjects according to BMI.
BMI < 25 (n = 83)
Age (years)

44.29 ± 20.72

Sex (F/M)

56/27

Waist circumference (cm)

80.85 ± 8.91

Waist/hip ratio

0.83 ± 0.07

BMI (kg/m2)

21.57 ± 2.27

Leptin (ng/mL)

21.98 ± 21.61

Leptin receptor (ng/mL)

30.24 ± 17.99

Total cholesterol (mg/dL)

192.84 ± 41.53

Triglyceride (mg/dL)

83.50 ± 40.75

LDL-cholesterol (mg/dL)

117.67 ± 37.79

HDL-cholesterol (mg/dL)

58.33 ± 13.17

HbA1c (%)

5.15 ± 0.646

Insulin (µU/mL)

7.2 ± 3.02

BMI ≥ 25 (n = 119)
25 ≤ BMI < 30
51.52 ± 16.44
51.05 ± 16.72
52/67
23/44
100.55 ± 10.20
94.92 ± 7.6
0.89 ± 0.08
0.89 ± 0.07
31.01 ± 6.12
27.34 ± 1.48
36.30 ± 35.56*
28.05 ± 31.89
23.39 ± 10.72**
24.74 ± 12.86
217.83 ± 44.19
217.79 ± 42.55
135.87 ± 76.41
136.49 ± 90.2
139.50 ± 42.22
139.31 ± 36.2
49.79 ± 12.18
51.34 ± 12.78
5.79 ± 0.93
5.66 ± 0.8
14.69 ± 8.41
13.72 ± 9.19

BMI ≥ 30
52.57 ± 15.88
29/23
106.61 ± 10.67
0.88 ± 0.08
35.61 ± 6.95
47.11 ± 37.40
22.31 ± 9.42
214.42 ± 45.57
132.51 ± 47.28
136.71 ± 48.91
47.93 ± 10.88
5.94 ± 1.04
15.45 ± 6.88

Number of individuals in parentheses. Values are reported as mean ± standard deviation (SD)
or number of patients. P < 0.05 was considered significant.
*Leptin levels were significantly higher in BMI ≥ 25 kg/m2 group than in < 25 kg/m2 one (P =
0.003).
**Leptin receptor levels were significantly lower in BMI ≥ 25 kg/m2 group than in < 25 kg/m2
one (P = 0.002).
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method based on sodium dodecyl sulfate lysis, ammonium
acetate extraction, and ethanol precipitation (10).
2.4. Polymorphism analyses
We followed previously described methods for leptin and
leptin receptor polymorphisms (9).
The
primers
used
for
PCR
for
the
leptin
G2548A
polymorphism
were
F(5΄TTTCCTGTAATTTTCCCGTGA-3΄)
and
R(5΄AAAGCAAAGACAGGCATAAAA-3΄); and for the leptin
receptor Q223R polymorphism, the primer sequences were
F(5΄-ACCCTTTAAGCTGGGTGTCCCAAATAG-3΄) and
R (5΄-AGCTAGCAAATATTTTTGT AAGCAATT-3΄)
from IDT (Integrated DNA Technologies, Inc.). Leptin
gene regions were amplified under following conditions:
a reaction mixture containing approximately 100
ng of template DNA, 10 pmol of each primer, all 4
deoxyribonucleoside 5΄ triphosphates (each at 1 mM),
2 mM MgCl2, and 0.5 U of Taq polymerase in 10X
reaction buffer (MBI Fermentas). For leptin receptor gene
amplification, the following reaction mixture was used:
approximately 100 ng of template DNA, 10 pmol of each
primer, all 4 deoxyribonucleoside 5΄ triphosphates (each
at 1 mM), 2 mM MgCl2, and 0.3 U of Taq polymerase in
10X reaction buffer (MBI Fermentas). For both leptin
and leptin receptor gene amplifications, reactions were
carried out with an initial melting step of 3 min at 94 °C,
followed by 33 cycles of 30 s at 94 °C, 30 s at 60 °C, 30
s at 72 °C, and a final elongation step of 5 min at 72 °C.
PCR and restriction products were electrophoresed in 2%
(w/v) agarose gels and stained with ethidium bromide.
The restriction endonuclease was Hin6I to distinguish
the leptin-2548 G/A polymorphism. Hin6I digestion
generated 181 bp and 61 bp fragments for the G allele, but
an uncut 242 bp fragment for the A allele. CfoI restriction
endonuclease enzyme was used for the leptin receptor
gene. The expected products were 294 bp and 127 bp
fragments for the R allele and a single uncut fragment of
421 bp for the Q allele.

2.5. Serum level detection
Leptin and soluble leptin receptor levels were determined
by using commercial ELISA kits (Biovendor for leptin
receptor and Biosource for leptin).
2.6. Statistical analysis
Statistical analyses were performed using SPSS version
11.5 (SPSS Inc, Chicago, IL, USA) including the chi-square
test, Fischer’s exact test, and the Pearson correlation test.
Odds ratios and 95% confidence intervals were calculated.
Mean values were compared among subjects by unpaired
Kruskal-Wallis analysis. Values of P < 0.05 were considered
statistically significant.
3. Results
The study group was divided into subgroups according
to body mass index (BMI); demographic details of those
subgroups are given in Table 1.
Mean circulating leptin and leptin receptor levels
according to the leptin G2548A genotype and allele are
shown in Table 2. Leptin levels were significantly higher
in subjects with the AA genotype than in those with
the AG or GG genotype (P < 0.01). However, we found
leptin receptor levels to be lower in subjects with the AA
genotype than in those with the AG genotype (P < 0.01).
Leptin receptor levels did not significantly differ between
subjects with the A allele and those without the A allele (P
> 0.05). Leptin levels were significantly higher in subjects
with the A allele than in subjects without the A allele (P =
0.026). Furthermore, leptin levels were higher in subjects
without the G allele than in those with it (P < 0.01). In
contrast, decreased leptin receptor levels were found in
subjects without the G allele in comparison to those who
carried the G allele (P < 0.01). Mean circulating leptin and
leptin receptor levels according to leptin receptor Q223R
genotypes and alleles are given in Table 3. There were no
statistically significant differences among any of these
groups (P > 0.05).

Table 2. Mean circulating leptin and leptin receptor levels according to leptin G2548A genotypes and alleles.
Leptin G2548A genotypes

Leptin levels (ng/mL)*
Leptin receptor levels
(ng/mL)**

Leptin G2548A alleles

AA
(n = 22)

AG
(n = 65)

GG
(n = 25)

63.73 ± 48.4

28.96 ± 27.61 24.84 ± 19.12 37.75 ± 37.03 24.84 ± 19.12 27.82 ± 25.50 63.73 ± 48.43

16.42 ± 5.62

26.48 ± 13.84 27.27±10.58

A+

A–

G+

G–

23.94 ± 13.03 27.27 ± 10.58 26.70 ± 12.97 16.42 ± 5.62

Data presented as mean ± standard deviation.
*Leptin levels were higher for the AA genotype than the others (P < 0.01). Leptin levels were higher in subjects with the A allele than in
those without it (P = 0.026) and higher in subjects without the G allele than in those with it (P < 0.01).
**Leptin receptor levels were lower for AA compared to the others (P < 0.01). Leptin receptor levels were lower in subjects without the
G allele than in those with it (P < 0.01).
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Table 3. Mean circulating leptin and leptin receptor levels according to leptin receptor Q223R genotype and allele.

Leptin levels

Leptin receptor Q223R genotypes

Leptin receptor Q223R alleles

QQ (n = 47)

Q+

QR (n = 51)

RR (n = 13)

Q–

R+

R–

35.31 ± 35.30 33.68 ± 32.14 39.17 ± 41.67 34.46 ± 33.53 39.17 ± 41.67 34.80 ± 34.00 35.31 ± 35.30

Leptin receptor levels 25.42 ± 11.65 23.67 ± 14.15 25.56 ± 8.23

24.51 ± 12.97 25.56 ± 8.23

24.06 ± 13.13 25.42 ± 11.65

Data presented as mean ± standard deviation.

Combined analysis was conducted to assess the
cumulative effects of possible risk or protective attributes
of the alleles. When combined analysis of leptin G2548A
and leptin receptor Q223R genotypes was evaluated, there
were no significant differences in the subjects (P = 0.497)
(Table 4).
Moreover, we analyzed leptin and leptin receptor
levels among the subjects, who were divided into 2 groups
according to the BMI results < 25 kg/m2 and ≥ 25 kg/m2.
The latter group was further divided into 2 subgroups with
25 kg/m2 ≤ BMI < 30 kg/m2 and BMI ≥ 30 kg/m2 (Table 1).
We found that leptin levels were significantly higher and
leptin receptor levels were significantly lower in subjects
with BMI ≥ 25 kg/m2 than in those with BMI < 25 kg/m2
(P = 0.003, P = 0.002). When we assessed other clinical
parameters in the study group, there were no statistically
significant differences among the subjects according to
their BMI values (P > 0.05) (Table 1).
4. Discussion
Leptin is an essential hormone secreted from adipose
tissue and it is related to weight gain and obesity. The
serum levels of adipose tissue-derived hormones are
known to affect insulin sensitivity (11). In a previous
study, it was found that serum leptin concentrations were
decreasing while soluble leptin receptor concentrations
were increasing after a very-low-calorie diet in obese
women (11). In type 2 diabetes cases, it was found that
circulating leptin receptor levels were inversely correlated
with the risk of type 2 diabetes (3).

Enhanced release of leptin was found to be
accompanied with decreased soluble leptin receptor levels,
causing leptin resistance over time (5,12). Our results were
in accordance with these previous findings. In our study,
we evaluated the differences between normal (<25 kg/m2),
overweight (25 kg/m2 ≤ BMI < 30 kg/m2), and obese (≥
30 kg/m2) subjects. Comparing those 3 groups with each
other, leptin levels were found to be higher in obese cases,
not in overweight ones; and leptin receptor levels were
higher in normal subjects, not in overweight or obese ones.
Obesity is a polygenic disorder with several candidate
genes playing a role in determining the final severity of
obesity. Leptin and leptin receptor genes are 2 of those
candidate genes to be evaluated. There are several different
studies focusing not only their levels, but also on possible
effects of their polymorphic genes on the severity of weight
gain.
We studied not only the levels of leptin and leptin
receptors, but also their polymorphisms, leptin G2548A
and leptin receptor Q223R. In a previous study in an Asian
population, it was found that the leptin G2548A variant
was significantly associated with extreme obesity (≥35
kg/m2), but not with moderate obesity (≥27 kg/m2), (8).
In another study, no relationship was found between the
same leptin polymorphism and obesity-related variables
such as BMI and waist circumference, but a positive
correlation was found between GG genotype and leptin
receptor levels (13).
In a study of a Turkish population, no relationship was
found between the leptin receptor Q223R polymorphism

Table 4. The frequencies of haplotypes of leptin G-2548A and leptin receptor
Q223R gene polymorphisms in subjects.
Leptin receptor genotypes

Haplotype
association
AA
Leptin genotypes

QR n (%)

RR n (%)

QQ n (%)

18 (56.3)

3 (9.4)

11 (34.4)

AG

32 (39.5)

10 (12.3)

39 (48.1)

GG

9 (9.6)

4 (2.8)

9 (9.6)

Data are presented as number of subjects, with frequency in parentheses.
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and BMI, which was in parallel with our results (14). In
a previous study in a Romanian population, it was found
that the leptin receptor Q223R polymorphism was not
associated with obesity, but the R allele was concluded
to be a possible predisposing factor for obesity (13). In
our study, leptin levels were higher in homozygote leptin
AA subjects than in those with AG or GG genotypes, in
contrast to the decreased leptin receptor levels between the
same groups. Leptin levels were lower in subjects with the
G allele than in those without it. However, no relationship
between leptin or leptin receptor levels and leptin receptor
genotypes could be determined. No statistically significant
relationship was observed between any leptin–leptin
receptor genotype distributions either.
Mendez-Sanchez et al. determined that the leptin
receptor Q223R polymorphism was more frequent in

subjects with higher BMI (15), but we did not determine
such a leptin receptor genotype or allele difference between
normal (<25 kg/m2) and overweight (≥25 kg/m2) subjects.
Our results were in parallel with those of a previous study
in a Japanese population (16).
Ours was a rare study evaluating both levels and
common polymorphisms of leptin and leptin receptors.
Obesity is an important disease predisposing to more
serious problems. Therefore, it has to be investigated in
further detail. We obtained interesting results that warrant
further elaboration. Therefore, in subsequent studies we
are planning to increase the numbers of subjects in the
case and control groups and to investigate the relationships
between those parameters and chronic diseases related to
obesity.
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